- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
IPCA Labs, Cadila Healthcare among 16 Indian pharma firms blacklisted in Nepal
![IPCA Labs, Cadila Healthcare among 16 Indian pharma firms blacklisted in Nepal IPCA Labs, Cadila Healthcare among 16 Indian pharma firms blacklisted in Nepal](https://medicaldialogues.in/h-upload/2022/10/20/750x450_188554-banned-new.webp)
Kathmandu: In a major setback, Nepal has banned import of medicines from 16 Indian pharmaceutical companies including IPCA Laboratories, Cadila Healthcare, Baba Ramdev promoted Divya Pharmacy for allegedly failing to comply with the World Health Organization's (WHO) Good Manufacturing Practices (GMP).
Nepal's Department of Drug Administration has released a list of 16 Indian pharmaceutical companies. IPCA Labs in South Sikkim and Ahmedabad-based Cadila Healhcare have also been mentioned in the list that do not comply regulatory compliance apart from Divya Pharmacy, which is part of yoga guru Ramdev's business conglomerate Patanjali Ayurved.
Publication of the list by the department, the national regulatory body of the drugs markets, both allopathic and ayurveda, means that medicines manufactured by those companies cannot be imported to Nepal, according to the Kathmandu Post daily.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751